Hypoxia-inducible factor 2α: a novel target in gliomas

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93(4), 266–276 (2001).
  Medline CASGoogle Scholar
• 2 Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells – a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev. Biol. 16, 554–563 (2005).
  Medline CASGoogle Scholar
• 3 Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nat. Rev. Cancer 2(1), 38–47 (2002).
  Medline CASGoogle Scholar
• 4 Heddleston JM, Hitomi M, Venere M et al. Glioma stem cell maintenance: the role of the microenvironment. Curr. Pharm. Des. 17(23), 2386–2401 (2011).
  Medline CASGoogle Scholar
• 5 Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12(1), 9–22 (2012).
  CASGoogle Scholar
• 6 Yu T, Tang B, Sun X. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med. J. 58(3), 489 (2017).
  Medline CASGoogle Scholar
• 7 Colwell N, Larion M, Giles AJ et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro. Oncol. 19(7), 887–896 (2017).
  Medline CASGoogle Scholar
• 8 Brat DJ, Castellano-Sanchez AA, Hunter SB et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 64(3), 920–927 (2004).
  Medline CASGoogle Scholar
• 9 Kayama T, Yoshimoto T, Fujimoto S, Sakurai Y. Intratumoral oxygen pressure in malignant brain tumor. J. Neurosurg. 74(1), 55–59 (1991).
  Medline CASGoogle Scholar
• 10 Meixensberger J, Dings J, Kuhnigk H, Roosen K. Studies of tissue PO2 in normal and pathological human brain cortex. Acta Neurochir. Suppl. 59, 58–63 (1993).
  Medline CASGoogle Scholar
• 11 Gerstner ER, Zhang Z, Fink JR et al. ACRIN 6684: assessment of tumor hypoxia in newly diagnosed glioblastoma using 18F-FMISO PET and MRI. Clin. Cancer Res. 22, 5079–5086 (2016).
  Medline CASGoogle Scholar
• 12 Yamamoto Y, Maeda Y, Kawai N et al. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl. Med. Commun. 33(6), 621–625 (2012).
  Medline CASGoogle Scholar
• 13 Dong S, Nutt CL, Betensky RA et al. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J. Neuropathol. Exp. Neurol. 64(11), 948–955 (2005).
  MedlineGoogle Scholar
• 14 Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 51(1), 2–12; discussion 12–13 (2002).
  MedlineGoogle Scholar
• 15 Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann. Intern. Med. 138(8), 659–668 (2003).
  MedlineGoogle Scholar
• 16 Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20), 3274–3284 (2009). • Discusses hypoxia as a trigger for promoting glioblastoma stem cell formation and provides in vivo evidence for hypoxia-inducible factor 2α (HIF2α)-positive effect on flank glioma growth.
  Medline CASGoogle Scholar
• 17 Ponnala S, Veeravalli KK, Chetty C, Dinh DH, Rao JS. Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice. PLoS ONE 6(10), e26191 (2011).
  Medline CASGoogle Scholar
• 18 Koivunen P, Lee S, Duncan CG et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483(7390), 484–488 (2012).
  Medline CASGoogle Scholar
• 19 Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11(6), 393–410 (2011). •• Summarizes the malignant effects of hypoxia in cancer and outlines antihypoxia therapeutic approaches including bioreductive prodrugs and molecular inhibitors of the hypoxia pathway.
  Medline CASGoogle Scholar
• 20 Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS. Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer 3(7), 529–541 (2017).
  Medline CASGoogle Scholar
• 21 Schöning JP, Monteiro M, Gu W. Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α. Clin. Exp. Pharmacol. Physiol. 44(2), 153–161 (2017).
  MedlineGoogle Scholar
• 22 Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12(12), 5447–5454 (1992). • One of the earliest descriptions of HIFs during their discovery.
  Medline CASGoogle Scholar
• 23 Taylor CT, McElwain JC. Ancient atmospheres and the evolution of oxygen sensing via the hypoxia-inducible factor in metazoans. Physiology 25(5), 272–279 (2010).
  Medline CASGoogle Scholar
• 24 Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 7(3), 205–213 (1998).
  Medline CASGoogle Scholar
• 25 Slemc L, Kunej T. Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature. Tumor Biol. 37(11), 14851–14861 (2016).
  Medline CASGoogle Scholar
• 26 Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70(5), 1469–1480 (2006).
  Medline CASGoogle Scholar
• 27 Denko NC, Fontana LA, Hudson KM et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22(37), 5907–5914 (2003).
  Medline CASGoogle Scholar
• 28 Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92(12), 5510–5514 (1995).
  Medline CASGoogle Scholar
• 29 Semenza GL, Agani F, Booth G et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 51(2), 553–555 (1997).
  Medline CASGoogle Scholar
• 30 Mole DR, Blancher C, Copley RR et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 284(25), 16767–16775 (2009). •• Given emerging evidence for biologically distinct functions of HIF1α versus HIF2α genome-wide chromatin immunoprecipitation gene identified individual gene transcription targets specific to each transcription factor. Understanding the genes implicated in each HIF will aid to the biologic understanding of their unique roles in diseases including cancer.
  Medline CASGoogle Scholar
• 31 Takeda N, O'Dea EL, Doedens A et al. Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev. 24(5), 491–501 (2010).
  Medline CASGoogle Scholar
• 32 Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug Discov. 13(11), 852–869 (2014).
  Medline CASGoogle Scholar
• 33 Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl. 5), 4–9 (2004).
  MedlineGoogle Scholar
• 34 Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26(312), 638–648 (1953).
  Medline CASGoogle Scholar
• 35 Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin. Oncol. 28(2 Suppl., 8), 49–53 (2001).
  Medline CASGoogle Scholar
• 36 Jeong W, Rapisarda A, Park SR et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother. Pharmacol. 73(2), 343–348 (2014).
  Medline CASGoogle Scholar
• 37 Tibes R, Falchook GS, Von Hoff DD et al. Results from a Phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. J. Clin. Oncol. 28(15 Suppl.), 3076–3076 (2010).
  MedlineGoogle Scholar
• 38 López-Lázaro M. Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev. 15(12), 2332–2335 (2006).
  Medline CASGoogle Scholar
• 39 Soni S, Padwad YS. HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol. 56(4), 503–515 (2017).
  Medline CASGoogle Scholar
• 40 Wallace E. PT2385: HIF-2a antagonist for the treatment of VHL mutant ccRCC. Proceedings of: 12th International VHL Medical Symposium. MA, USA, 7–9 April 2016.
  Google Scholar
• 41 Nickerson ML, Jaeger E, Shi Y et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14(15), 4726–4734 (2008).
  Medline CASGoogle Scholar
• 42 Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr. Oncol. Rep. 11(2), 94–101 (2009).
  Medline CASGoogle Scholar
• 43 Sato Y, Yoshizato T, Shiraishi Y et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45(8), 860–867 (2013).
  Medline CASGoogle Scholar
• 44 Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7(1), 85–90 (1994).
  Medline CASGoogle Scholar
• 45 Toledo RA. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 24(9), C9–C19 (2017). •• Discusses cancers with known HIF2α mutations and the recently developed, specific HIF2α inhibitors (PT2385 and PT2399) under investigation for renal cell carcinoma and suggests these drugs may be of use in other malignancies with gain-of-function HIF2α mutations including pheochromocytoma and paragranglioma.
  Medline CASGoogle Scholar
• 46 Schödel J, Grampp S, Maher ER et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur. Urol. 69(4), 646–657 (2016).
  MedlineGoogle Scholar
• 47 Sun X, Liu M, Wei Y et al. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther. 13(4), 428–435 (2006).
  Medline CASGoogle Scholar
• 48 Rong Y, Durden DL, Van Meir EG, Brat DJ. “Pseudopalisading” necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol. 65(6), 529–539 (2006).
  MedlineGoogle Scholar
• 49 D'Alessio A, Proietti G, Lama G et al. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells. Oncotarget 7(48), 78541–78556 (2016).
  MedlineGoogle Scholar
• 50 Cooper LAD, Gutman DA, Chisolm C et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am. J. Pathol. 180(5), 2108–2119 (2012).
  Medline CASGoogle Scholar
• 51 Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3), 157–173 (2006).
  Medline CASGoogle Scholar
• 52 Tso C-L, Shintaku P, Chen J et al. Primary glioblastomas express mesenchymal stem-like properties. Mol. Cancer Res. 4(9), 607–619 (2006).
  Medline CASGoogle Scholar
• 53 Kim Y-W, Koul D, Kim SH et al. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro. Oncol. 15(7), 829–839 (2013).
  Medline CASGoogle Scholar
• 54 Li Z, Bao S, Wu Q et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6), 501–513 (2009). • In vitro and invivo evidences of HIF2α knockdown effect glioma stem cell and tumor growth along with animal survival.
  Medline CASGoogle Scholar
• 55 Pietras A, Johnsson AS, Påhlman S. The HIF-2α-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. Curr. Top. Microbiol. Immunol. 345, 1–20 (2010).
  Medline CASGoogle Scholar
• 56 Pietras A, Katz AM, Ekström EJ et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14(3), 357–369 (2014).
  Medline CASGoogle Scholar
• 57 Rimkus TK, Carpenter RL, Sirkisoon SR et al. Truncated glioma-associated oncogene homolog 1 (tGLI1) mediates mesenchymal glioblastoma via transcriptional activation of CD44. Cancer Res. 78(10), 2589–2600 (2018).
  Medline CASGoogle Scholar
• 58 Johansson E, Grassi ES, Pantazopoulou V et al. CD44 interacts with HIF-2α to modulate the hypoxic phenotype of perinecrotic and perivascular glioma cells. Cell Rep. 20(7), 1641–1653 (2017).
  Medline CASGoogle Scholar
• 59 Chaturvedi P, Gilkes DM, Takano N, Semenza GL. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc. Natl Acad. Sci. USA 111(20), E2120–E2129 (2014).
  Medline CASGoogle Scholar
• 60 Gilkes DM, Xiang L, Lee SJ et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc. Natl Acad. Sci. USA 111(3), E384–E393 (2014).
  Medline CASGoogle Scholar
• 61 Gilkes DM, Chaturvedi P, Bajpai S et al. Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res. 73(11), 3285–3296 (2013).
  Medline CASGoogle Scholar
• 62 Gilkes DM, Bajpai S, Wong CC et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol. Cancer Res. 11(5), 456–466 (2013).
  Medline CASGoogle Scholar
• 63 Wang X, Dong J, Jia L et al. HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma. Cancer Lett. 393, 113–124 (2017).
  Medline CASGoogle Scholar
• 64 Zhuang Z, Yang C, Ryska A et al. HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. Endocr. Relat. Cancer 23(5), L13–L16 (2016).
  MedlineGoogle Scholar
• 65 Toledo RA, Qin Y, Srikantan S et al. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 20(3), 349–359 (2013).
  Medline CASGoogle Scholar
• 66 Ferrandina G, Zannoni GF, Martinelli E et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12(9), 2774–2779 (2006).
  Medline CASGoogle Scholar
• 67 Bordji K, Grandval A, Cuhna-Alves L, Lechapt-Zalcman E, Bernaudin M. Hypoxia-inducible factor-2α (HIF-2α) but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells. FEBS J. 281(23), 5220–5236 (2014). • HIF1α dominates the early literature in hypoxia research, including hypoxia in oncology. An emerging role is being realized for HIF2α over HIF1α and this report provides evidence supporting HIF2α in glioma malignment behavior.
  Medline CASGoogle Scholar
• 68 Katsetos CD, Draber P, Kavallaris M. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer. Agents Med. Chem. 11(8), 719–728 (2011).
  Medline CASGoogle Scholar
• 69 Lee G, Auffinger B, Guo D et al. Dedifferentiation of glioma cells to glioma stem-like cells by therapeutic stress-induced HIF signaling in the recurrent GBM model. Mol. Cancer Ther. 15(12), 3064–3076 (2016).
  Medline CASGoogle Scholar
• 70 Auffinger B, Tobias AL, Han Y et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 21(7), 1119–1131 (2014).
  Medline CASGoogle Scholar
• 71 Mao X, Yan M, Xue X et al. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab. Investig. 91(7), 1068–1078 (2011).
  Medline CASGoogle Scholar
• 72 Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26(2), 271–278 (2008).
  Medline CASGoogle Scholar
• 73 Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin. Colorectal Cancer 4(Suppl. 2), S62–S68 (2004).
  Medline CASGoogle Scholar
• 74 Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15(6), 385–403 (2016).
  Medline CASGoogle Scholar
• 75 Zhang H, Qian DZ, Tan YS et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl Acad. Sci. USA 105(50), 19579–19586 (2008).
  Medline CASGoogle Scholar
• 76 Kong D, Park EJ, Stephen AG et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65(19), 9047–9055 (2005).
  Medline CASGoogle Scholar
• 77 Xia Y, Choi H-K, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem. 49, 24–40 (2012).
  Medline CASGoogle Scholar
• 78 Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1 C-terminal activation domain. Mol. Cell. Biol. 26(15), 5895–5907 (2006).
  Medline CASGoogle Scholar
• 79 Yeo E-J, Ryu J-H, Cho Y-S et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107(3), 916–923 (2006).
  Medline CASGoogle Scholar
• 80 Kirkpatrick J, Desjardins A, Quinn J et al. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. J. Clin. Oncol. 25(18 Suppl.), 2065–2065 (2007).
  Google Scholar
• 81 Erbel PJA, Card PB, Karakuzu O, Bruick RK, Gardner KH. Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 100(26), 15504–15509 (2003).
  Medline CASGoogle Scholar
• 82 Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK, Gardner KH. Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor. Proc. Natl Acad. Sci. USA 106(2), 450–455 (2009).
  Medline CASGoogle Scholar
• 83 Courtney KD, Infante JR, Lam ET et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36(9), 867–874 (2018).
  Medline CASGoogle Scholar
• 84 Wallace EM, Rizzi JP, Han G et al. A small-molecule antagonist of HIF2a is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 76(18), 5491–5500 (2016). •• Renal cell carcinoma is the first malignancy for testing the newly developed HIF2α inhibitor, PT2385 and this report summarizes the preclinical evidence that led to clinical trial testing.
  Medline CASGoogle Scholar
• 85 Bhagwat AS, Vakoc CR. Targeting transcription factors in cancer. Trends Cancer 1(1), 53–65 (2015).
  MedlineGoogle Scholar